Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2019-10-24 Board/Management Inform…
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd., a foreign private issuer. It announces the appointment of a new Chief Executive Officer, Dr. Oren Hershkovitz, including details about his background, compensation, and effective date. There is no financial data, earnings information, or detailed report content. The document is primarily an announcement of a management change. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is 3719 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2019-10-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Enlivex Therapeutics Ltd., reporting the resignation of its CEO and the appointment of an interim CEO. It is a regulatory announcement about management changes but does not constitute a full management report or annual/quarterly financial report. The document length is 2416 characters, which is relatively short and primarily contains a management change notice. According to the filing definitions, announcements of changes in senior management fall under 'Board/Management Information' (MANG). Therefore, the appropriate classification is MANG with high confidence.
2019-09-30 English
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2019-09-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Investor Presentation Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Enlivex Therapeutics Ltd., with the SEC. It announces a corporate presentation at an investment conference and includes the presentation slides as an exhibit. The text does not contain detailed financial statements or substantive financial data but rather serves as an announcement and provision of presentation materials. The document length is short (2198 characters), and it primarily informs about the presentation event and provides the slides. According to the classification rules, such documents are best classified as Investor Presentation (IP) since it is a detailed presentation for investors focusing on financials, strategy, and market position, rather than a full report or regulatory filing. It is not a report publication announcement or a regulatory filing since it includes the presentation slides as an exhibit, which is typical for investor presentations in Form 6-K filings.
2019-09-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about an ongoing clinical trial and is dated August 19, 2019. The document is short (1929 characters) and primarily serves as a regulatory filing to inform the market about recent developments. It does not contain detailed financial statements or comprehensive financial analysis, nor is it an annual or quarterly report. It also does not fit into categories like earnings release, management report, or capital update. Given the nature of Form 6-K filings, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-08-19 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Enlivex Therapeutics Ltd., with the SEC. It contains unaudited consolidated financial statements for the three and six-month periods ended June 30, 2019 and 2018, and an Operating and Financial Review and Prospects for the same periods. The Form 6-K is used to furnish interim or other periodic reports by foreign private issuers. The presence of financial statements and operating review for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 2549 characters, which is consistent with a Form 6-K filing containing substantive financial data rather than just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2019-07-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.